Results 231 to 240 of about 608,296 (310)
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam+9 more
wiley +1 more source
Cell and Developmental Biology—A Shared Past, an Intertwined Future [PDF]
Rachel E. Dawes-Hoang, Eric Wieschaus
openalex +1 more source
Patient engagement involves actively including patients in healthcare decisions and research to ensure care and studies align with their needs. This approach improves outcomes, trust, and communication while fostering collaboration between patients and professionals.
Estela Cepeda+3 more
wiley +1 more source
Linking molecular biology to clinical advances in developmental neurology
Alan K. Percy
openalex +1 more source
When developmental biology meets human pathology [PDF]
Gérard Karsenty
openalex +1 more source
Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM
CircRNAs are differentially expressed in glioblastoma primary tumors and might serve as therapeutic targets and diagnostic markers. The investigation of circRNA and RNA‐binding proteins (RBPs) interactions shows that distinct RBPs play a role in circRNA biogenesis and function.
Julia Latowska‐Łysiak+14 more
wiley +1 more source
Etiology and Morphogenesis of Congenital Heart Disease: Twenty Years of Progress in Genetics and Developmental Biology [PDF]
openalex +1 more source
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini+10 more
wiley +1 more source